JP2020028300A5 - - Google Patents

Download PDF

Info

Publication number
JP2020028300A5
JP2020028300A5 JP2019201128A JP2019201128A JP2020028300A5 JP 2020028300 A5 JP2020028300 A5 JP 2020028300A5 JP 2019201128 A JP2019201128 A JP 2019201128A JP 2019201128 A JP2019201128 A JP 2019201128A JP 2020028300 A5 JP2020028300 A5 JP 2020028300A5
Authority
JP
Japan
Prior art keywords
mutation
pik3ca
sequence
polynucleotide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019201128A
Other languages
English (en)
Japanese (ja)
Other versions
JP6694543B2 (ja
JP2020028300A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020028300A publication Critical patent/JP2020028300A/ja
Publication of JP2020028300A5 publication Critical patent/JP2020028300A5/ja
Application granted granted Critical
Publication of JP6694543B2 publication Critical patent/JP6694543B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2019201128A 2004-03-02 2019-11-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異 Expired - Lifetime JP6694543B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
US60/548,886 2004-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018090580A Division JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020038337A Division JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Publications (3)

Publication Number Publication Date
JP2020028300A JP2020028300A (ja) 2020-02-27
JP2020028300A5 true JP2020028300A5 (https=) 2020-04-16
JP6694543B2 JP6694543B2 (ja) 2020-05-13

Family

ID=35056655

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2007501815A Withdrawn JP2007530017A (ja) 2004-03-02 2005-02-18 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2012052427A Expired - Lifetime JP5336620B2 (ja) 2004-03-02 2012-03-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2013100073A Expired - Lifetime JP5894110B2 (ja) 2004-03-02 2013-05-10 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2015245769A Expired - Lifetime JP6250017B2 (ja) 2004-03-02 2015-12-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2017202265A Expired - Lifetime JP6395917B2 (ja) 2004-03-02 2017-10-19 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2018090580A Expired - Lifetime JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2019201128A Expired - Lifetime JP6694543B2 (ja) 2004-03-02 2019-11-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020038337A Expired - Lifetime JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020078786A Expired - Lifetime JP7001735B2 (ja) 2004-03-02 2020-04-28 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2022022542A Expired - Lifetime JP7304987B2 (ja) 2004-03-02 2022-02-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2007501815A Withdrawn JP2007530017A (ja) 2004-03-02 2005-02-18 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2012052427A Expired - Lifetime JP5336620B2 (ja) 2004-03-02 2012-03-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2013100073A Expired - Lifetime JP5894110B2 (ja) 2004-03-02 2013-05-10 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2015245769A Expired - Lifetime JP6250017B2 (ja) 2004-03-02 2015-12-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2017202265A Expired - Lifetime JP6395917B2 (ja) 2004-03-02 2017-10-19 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2018090580A Expired - Lifetime JP6695381B2 (ja) 2004-03-02 2018-05-09 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020038337A Expired - Lifetime JP7169315B2 (ja) 2004-03-02 2020-03-06 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2020078786A Expired - Lifetime JP7001735B2 (ja) 2004-03-02 2020-04-28 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
JP2022022542A Expired - Lifetime JP7304987B2 (ja) 2004-03-02 2022-02-17 ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Country Status (14)

Country Link
US (6) US8026053B2 (https=)
EP (5) EP2497836B1 (https=)
JP (10) JP2007530017A (https=)
AU (2) AU2005227148B2 (https=)
CA (1) CA2560696C (https=)
CY (1) CY1121975T1 (https=)
DK (3) DK3296407T3 (https=)
ES (5) ES2869167T3 (https=)
HU (1) HUE045690T2 (https=)
LT (1) LT3296407T (https=)
PL (2) PL1730303T3 (https=)
PT (3) PT1730303E (https=)
SI (2) SI3296407T1 (https=)
WO (1) WO2005091849A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3296407T1 (sl) 2004-03-02 2019-09-30 The Johns Hopkins University Mutacije gena PIK3CA pri rakih pri ljudeh
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US7863437B2 (en) 2007-12-03 2011-01-04 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of PIK3CA expression
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
US20110236916A1 (en) * 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法
US9157125B2 (en) 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
ES2625288T3 (es) 2011-04-15 2017-07-19 The Johns Hopkins University Sistema de secuenciación segura
RU2014107713A (ru) * 2011-07-28 2015-09-10 Дженентек, Инк Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
AU2013338393C1 (en) 2012-10-29 2024-07-25 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
CN108130373A (zh) * 2013-03-13 2018-06-08 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
EP3027654B1 (en) * 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
EP4234722A3 (en) 2014-03-31 2023-09-20 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
RS59710B1 (sr) 2014-08-07 2020-01-31 Pharmassist Ltd Metod određivanja mutacionog statusa pik3ca u uzorku
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
EP4435112A3 (en) * 2015-05-27 2025-02-26 Quest Diagnostics Investments Incorporated Compositions and methods for screening solid tumors
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN108138235B (zh) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
JP2018535997A (ja) 2015-12-03 2018-12-06 ノバルティス アーゲー ｃｔＤＮＡにＰＩＫ３ＣＡ変異を有するために事前選択された患者におけるＰＩ３Ｋ阻害剤を用いた癌の処置
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
CA3020628A1 (en) 2016-04-14 2017-10-19 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
CN110431241B (zh) 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
JP7224645B2 (ja) * 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
US10975443B2 (en) 2017-11-30 2021-04-13 Mayo Foundation For Medical Education And Research Detecting breast cancer
JP2023513606A (ja) 2020-02-14 2023-03-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 核酸を評価するための方法および材料
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
WO2001016306A2 (en) 1999-08-27 2001-03-08 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
CA2395872A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
WO2004010900A1 (en) 2002-07-25 2004-02-05 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
KR20070087266A (ko) * 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
SI3296407T1 (sl) 2004-03-02 2019-09-30 The Johns Hopkins University Mutacije gena PIK3CA pri rakih pri ljudeh

Similar Documents

Publication Publication Date Title
JP2020028300A5 (https=)
Carvalhais et al. Molecular diagnostics of banana fusarium wilt targeting secreted-in-xylem genes
JP2016500110A5 (https=)
JP2009538607A5 (https=)
PH12017502200A1 (en) Methods of diagnosing and treating cancer
JP2016513094A5 (https=)
CN115424666B (zh) 一种基于全基因组重亚硫酸盐测序数据筛选泛癌早筛分子标志物的方法及系统
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
EA202092900A3 (ru) Мутационный анализ днк в плазме для детектирования рака
JP2013066474A5 (https=)
TWI670495B (zh) 一種鑑定樣本中腫瘤負荷的方法和系統
JP2015523569A5 (https=)
CY1125388T1 (el) Πολυπλεγμενη παραλληλη αναλυση εμπλουτισμενη σε στοχους για την αξιολογηση βιοδεικτων ογκου
JP2009516178A5 (https=)
Steinhagen et al. Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection
Vinayanuwattikun et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer
CN105200122B (zh) 小麦条锈菌的定量检测试剂盒及其应用
JP2019529959A5 (https=)
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
CN108893533B (zh) 用于预测或辅助预测肺部辐射后患放射性肺炎风险的试剂盒
BR112021023247A2 (pt) Métodos de diagnóstico e tratamento do câncer cervical
Niblock et al. Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma
RU2565554C2 (ru) СПОСОБ ДИФФЕРЕНЦИАЦИИ БИОВАРОВ И ГЕНОВАРИАНТОВ ШТАММОВ Yersinia pestis ОСНОВНОГО ПОДВИДА С ПОМОЩЬЮ ПОЛИМЕРАЗНОЙ ЦЕПНОЙ РЕАКЦИИ
JP6323829B2 (ja) コンブの原産国判別方法並びにプライマー及びプライマーを含むキット
JP2016123340A (ja) 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤